[Pulmonary hypertension]

Internist (Berl). 2002 Dec;43(12):1498, 1501-9. doi: 10.1007/s00108-002-0761-z.

[Article in German]

Authors

H Olschewski¹, A Ghofrani, R Wiedemann, F Rose, B Enke, T Gessler, R Voswinckel, M Kohstall, F Grimminger, W Seeger

Affiliation

¹ Medizinische Klinik und Poliklinik II, Universitätsklinikum Giessen. [email protected]

PMID: 12607389
DOI: 10.1007/s00108-002-0761-z

No abstract available

Publication types

Review

MeSH terms

Antihypertensive Agents / adverse effects
Antihypertensive Agents / therapeutic use*
Calcium Channel Blockers / adverse effects
Calcium Channel Blockers / therapeutic use
Endothelin Receptor Antagonists*
Epoprostenol / adverse effects
Epoprostenol / analogs & derivatives
Epoprostenol / therapeutic use
Humans
Hypertension, Pulmonary / diagnosis
Hypertension, Pulmonary / drug therapy*
Hypertension, Pulmonary / etiology
Vasodilator Agents / adverse effects
Vasodilator Agents / therapeutic use*

Substances

Antihypertensive Agents
Calcium Channel Blockers
Endothelin Receptor Antagonists
Vasodilator Agents
Epoprostenol